Related Experiment Video
Updated: Aug 14, 2026

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration
Published on: March 17, 2018
Modulation of the contact hypersensitivity response by AE-941 (Neovastat), a novel antiangiogenic agent
E Dupont1, B Wang, A J Mamelak
1AEterna Laboratories, Quebec, Quebec, Canada.
Background:
AE-941 (Neovastat) is an angiogenesis inhibitor noted to have antiinflammatory properties.
Objective:
We tested Neovastat in a contact hypersensitivity (CHS) model to determine the mechanism of action of its antiinflammatory effects.
Methods:
Neovastat was orally administered (200 mg/kg/day) during the sensitization and challenge phases of a murine CHS assay and inflammatory responses were measured. Subsequent assays were performed on mice treated with Neovastat or Cortisone (120 mg/kg/day, IP) and differential mRNA expression of several pro- and antiinflammatory cytokines was quantified using RT-PCR.
Results:
Neovastat decreased inflammation by 39% when administered during sensitization but did not alter the CHS response when given during the challenge phase. Neovastat significantly induced IL-10 expression in skin and skin-draining lymph nodes (49% and 45%, respectively) and decreased IFNgamma expression in the lymph nodes (35%).
Conclusion:
Antiinflammatory effects of Neovastat observed in CHS could be linked to modulation of cytokines early in the sensitization phase.
Related Concept Videos
Mechanism of Angiogenesis
Regulation of Angiogenesis and Blood Supply
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Tumor Immunotherapy
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hypersensitivity Reactions: Cytolytic Reactions

